Varda Raises $251M Series D at $1.6B Valuation to Scale In-Space Drug Manufacturing

The Deal: $251M at a $1.6B Valuation

Varda Space Industries announced a $251 million Series D on Sept. 30, 2026, one of the larger single raises to date for a company whose entire business model depends on getting things back down from orbit. The round reportedly values the El Segundo, California-based company at $1.6 billion.

With the new money in hand, Varda's total capital raised now stands at $598 million — a figure one source rounded up to "nearly $600M." That is a substantial war chest for a company that flew its first mission only in 2023.

Who's Backing It

The Series D was co-led by Lux Capital and Natural Capital. Participating investors included Founders Fund, Khosla Ventures, Caffeinated Capital, General Catalyst, 8090 Industries, Giant Step, and Also Capital — a roster that leans heavily toward firms with a track record of underwriting hardware-intensive, long-horizon bets.

Lux partner Shahin Farshchi framed the investment around execution rather than ambition, saying Varda is "the first and only company delivering a real cadence of launches and re-entries."

The Thesis: Why a Pharmaceutical Goes First

Varda's core bet is specific: the first product manufactured in space and consumed on Earth will be a drug. The reasoning is physical rather than commercial. In the absence of gravity, active pharmaceutical ingredients crystallize in ways that are impossible to reproduce on Earth, which opens the door to novel drug formulations that simply cannot be produced terrestrially.

Decades of microgravity research aboard the International Space Station have pointed in this direction without producing a commercial product. Varda positions itself as the only player that has assembled all three of the pieces required to change that:

• a launch cadence that can put processing hardware in orbit repeatedly
• a proven reentry capability to bring the product back
• an in-house pharmaceutical science team to work the chemistry

Reentry Cadence: Six Missions and Counting

Since its first mission launched in 2023, Varda has completed six successful reentry missions. More than a dozen additional launches and reentries are planned through 2028, which is the cadence story the company's investors keep returning to.

Among those flights, Varda and Southern Launch returned the W-5 capsule from orbit onto the Koonibba Test Range in Australia, reported in January 2026.

The W-Series Vehicle as a Hypersonic Testbed

Varda's W-Series capsules reach approximately Mach 25 on the way down from orbit — a flight regime that is notoriously difficult and expensive to replicate on the ground. The company pitches the vehicle to government and commercial partners as a reliable, repeatable system for returning materials and data.

That has turned the drug-processing platform into a second line of business. Beyond pharmaceuticals, Varda's capsules are used by semiconductor manufacturers and national security customers who want to test technology at hypersonic reentry speeds.

W-8 and W-9: Defense Payloads on Transporter-18

Two upcoming missions illustrate how far that second business has gone. W-8 and W-9 were both set to launch aboard SpaceX's Transporter-18 rideshare.

• W-8 carries reentry temperature and thermal protection sensors flown under a US military study.
• W-9 carries a Department of Defense payload to test hypersonic-flight navigation, along with advanced heat shield tiles from materials firm Syensqo.

Where the Money Goes

According to co-founder and President Delian Asparouhov, the new capital will go toward increasing mission cadence, deepening and expanding the company's pharmaceutical partnerships, and moving closer to delivering the first medicine made in space for patients on Earth.

That last item remains the milestone the entire thesis rests on. Six successful reentries have established that Varda can fly the loop; the Series D is about proving the loop produces a drug someone can take.